53 completed, 4 recruiting, 4 terminated, 3 unknown. 68 Phase 2, 10 Phase 1, 9 Phase 3.
Follow Enterovirus Infections: new trials by email Literature Review of Enterovirus Infections trials Research Report on Enterovirus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine+Inactivated Poliomyelitis Vaccine Made From Sabin Strains - Diphtheria, Pertussis | Phase 1 / Phase 2 | Recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 380 | 2026-10-11 | 2026-10-23 |
| Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 2 (nOPV2), Placebo (Sterile Water) - Poliomyelitis | Phase 2 | Recruiting | PATH | 675 | 2025-11-11 | 2026-01-09 |
| A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series LBVD, Pentavalent vaccine and Inactivated Polio vaccine - Diphtheria, Tetanus | Phase 2 / Phase 3 | Active not recruiting | LG Chem | 1186 | 2025-05-30 | 2026-09-03 |
| Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell). Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell), Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell), High-dose tetravalent inactivated enterovirus vaccine (Vero cell) ) - Hand, Foot, and Mouth Disease (HFMD), Herpangina | Phase 1 / Phase 2 | Completed | Sinovac Biotech Co., Ltd | 552 | 2025-01-15 | 2026-03-04 |
| A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose, VLP-Polio medium dose, VLP-Polio high dose - Poliomyelitis | Phase 1 / Phase 2 | Active not recruiting | CanSino Biologics Inc. | 480 | 2024-12-19 | 2026-08-06 |
| Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Novel oral poliomyelitis vaccine type 1 (nOPV1), Novel oral poliomyelitis vaccine type 2 (nOPV2), Novel oral poliomyelitis vaccine type 3 (nOPV3) - Poliomyelitis | Phase 1 / Phase 2 | Recruiting | PATH | 2400 | 2024-11-20 | 2025-06-03 |
| Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age LR20062, DTaP-HepB-IPV-Hib vaccine - Diphtheria, Tetanus | Phase 2 | Unknown | LG Chem | 336 | 2024-10-02 | 2024-10-01 |
| Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3), Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 (mOPV3) - Poliomyelitis | Phase 2 | Recruiting | PATH | 1532 | 2023-12-05 | 2026-05-11 |
| RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection Vapendavir, Placebo - COPD Exacerbation Acute, COPD With Acute Lower Respiratory Infection | Phase 2 | Completed | Altesa Biosciences, Inc. | 52 | 2023-11-20 | 2025-09-30 |
| Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated, medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated, high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated - Hand, Foot and Mouth Disease, Herpangina | Phase 1 / Phase 2 | Completed | Sinovac Biotech Co., Ltd | 744 | 2023-09-20 | 2026-06-26 |
| Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1), Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1) - Poliomyelitis | Phase 2 | Completed | PATH | 2232 | 2023-03-27 | 2026-09-25 |
| Immunogenicity nOPV2 With and Without bOPV Novel monovalent oral poliovirus vaccine type 2 (nOPV2), Bivalent oral poliovirus vaccine (bOPV) - Poliomyelitis | Phase 2 | Completed | Centers for Disease Control and Prevention | 795 | 2021-02-08 | 2024-10-04 |
| Clinical Trial of Novel OPV2 Vaccine novel oral polio type 2 vaccine (nOPV2), Placebo - Poliomyelitis | Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 330 | 2020-09-21 | 2022-08-30 |
| Comparison of Immunogenicity of Inactivated Poliovirus Vaccine (IPV) Administered Intramuscularly or Intradermally Inactivated poliovirus vaccine in reduced doses - Polio | Phase 2 | Completed | Instituto Nacional de Saúde, Mozambique | 382 | 2020-08-06 | 2024-01-31 |
| Safety & Immunogenicity of Enterovirus Type 71 Vaccine in Healthy Adults and Children 6-71months Inactivated Enterovirus Type 71 (EV71) Vaccine (Vero Cell) - Hand Foot & Mouth Disease | Phase 1 / Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 430 | 2019-12-24 | 2021-02-02 |
| Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants DTwP-HepB-Sabin IPV-Hib, Pentavalent vaccine and Salk IPV - Diphtheria, Tetanus | Phase 2 | Unknown | LG Chem | 336 | 2019-11-01 | 2019-09-06 |
| Hand, Foot, and Mouth Disease: Could EPs®7630 be a Treatment Option EPs® 7630 - Hand, Foot, and Mouth Disease | Phase 2 / Phase 3 | Completed | Eskisehir Osmangazi University | 240 | 2019-06-01 | 2024-04-09 |
| A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine nOPV2 (monovalent oral polio vaccine) - Poliomyelitis | Phase 2 | Completed | Fidec Corporation | 1025 | 2018-12-04 | 2024-01-19 |
| A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates Novel OPV2 candidate 1, Novel OPV2 candidate 2, Placebo - Poliomyelitis | Phase 2 | Completed | Pierre Van Damme | 250 | 2018-10-22 | 2021-10-15 |
| The Diabetes Virus Detection and Intervention Trial Ribavirin + Pleconaril, Placebos - Type1 Diabetes Mellitus, Enterovirus | Phase 2 | Completed | Oslo University Hospital | 96 | 2018-08-30 | 2021-04-08 |
Showing 20 of 68. Sign in to see all of them.
Poliomyelitis (43) · Tetanus (21) · Diphtheria (20) · Hepatitis B (18) · Haemophilus Infections (16) · Whooping Cough (11) · Hand, Foot and Mouth Disease (9) · Hepatitis A (6) · Herpangina (3) · Infections (3) · Postpoliomyelitis Syndrome (3) · Diabetes Mellitus, Type 1 (2) · RNA Virus Infections (2) · Virus Diseases (2)
Picornaviridae Infections (67) · RNA Virus Infections (66) · Virus Diseases (66) · Infections (65) · Central Nervous System Diseases (47) · Central Nervous System Infections (47) · Nervous System Diseases (47) · Neuroinflammatory Diseases (47) · Myelitis (46) · Neuromuscular Diseases (46) · Spinal Cord Diseases (46) · Digestive System Diseases (23) · Hepatitis (23) · Hepatitis, Viral, Human (23)
Poliovirus Vaccine, Inactivated (9) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (9) · Adjuvants, Pharmaceutic (4) · 13-valent pneumococcal vaccine (3) · Vaccines, Combined (3) · Hepatitis A Vaccines (2) · Immunoglobulins, Intravenous (2) · Pneumococcal Vaccines (2) · Rabies Vaccines (2) · Tetanus Toxoid (2) · Vaccines (2) · pleconaril (2) · 10-valent pneumococcal vaccine (1) · Acetaminophen (1) · Chickenpox Vaccine (1)
GlaxoSmithKline (11) · Sanofi Pasteur, a Sanofi Company (6) · LG Chem (5) · Sinovac Biotech Co., Ltd (5) · PATH (4) · Institute of Medical Biology, Chinese Academy of Medical Sciences (3) · Centers for Disease Control and Prevention (2) · Enimmune Corporation (2) · International Centre for Diarrhoeal Disease Research, Bangladesh (2) · Jiangsu Province Centers for Disease Control and Prevention (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Oslo University Hospital (2) · Ain Shams University (1) · Altesa Biosciences, Inc. (1) · Bayer (1)
China (11) · United States (6) · Bangladesh (5) · Canada (5) · Panama (5) · Poland (5) · Finland (4) · Germany (4) · Philippines (4) · Dominican Republic (3) · Belgium (2) · France (2) · Italy (2) · Norway (2) · Spain (2)
Yan-pin Li, MD (2) · Amanda Wilkinson, PhD (1) · Andre Vertruyen, MD (1) · Bridget Wills, MD (1) · Dang D Anh, PhD (1) · Edison Alberto, MD (1) · Edna Viegas, MD,PhD (1) · Elisabeth Farbu, MD, PhD (1) · Fengcai Zhu, Master (1) · Glacus S Brito, MD (1) · Ingrid Kromann (1) · Jingsi Yang (1)
PMID 22153001, PMID 28340322, PMID 32867698, PMID 40318674, PMID 20856164, PMID 21372751, PMID 22158682, PMID 23241989, PMID 23372725, PMID 24346596, PMID 25043278, PMID 25540274, PMID 26419198, PMID 26719058, PMID 26896318, PMID 27686833, PMID 27815383, PMID 28419204, PMID 28454674, PMID 29304199, PMID 30249424, PMID 31399275, PMID 31438878, PMID 33308427, PMID 33308429, PMID 33351072, PMID 33867179, PMID 36332645, PMID 36495882, PMID 37178706, PMID 38218668, PMID 38832001
2008 (1), 2009 (1), 2014 (1), 2015 (1), 2018 (1)